GeneDx Holdings WGS Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Total Revenue by Business | |||||
| GeneDx | $423.09M+40.0% | $302.29M+55.5% | $194.38M— | —— | |
| Total Revenue by Product | |||||
| Institutional customers | $69.8M+7.2% | $65.12M+9.4% | $59.5M+29.0% | $46.12M+45.4% | |
| Patients with third-party insurance | $345.24M+47.1% | $234.7M+74.5% | $134.49M-22.5% | $173.62M+2.5% | |
| Self-pay patients | $1.36M-41.9% | $2.34M+40.6% | $1.67M-78.0% | $7.59M+87.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does GeneDx Holdings break its business down?
- GeneDx Holdings (WGS) reports total revenue by business across 2 parts — GeneDx and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does GeneDx Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in GeneDx Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.